ArticleEvidence-based medicine2009

Rosiglitazone was non-inferior to metformin plus sulphonylurea for CV events but increased risk of HF and fractures in type 2 diabetes.

Lorraine L LipscombePubMed ↗Publisher ↗

No numbers read from the abstract.